NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
We hypothesise that the NRF2 transcription factor would act a biomarker of poor prognosis in colorectal cancer. We derived and validated an mRNA based metagene signature of NRF2 signalling and validated it in 1360 patients from 4 different datasets as an independent biomarker of poor prognosis. This is a novel insight into the molecular signalling of colorectal cancer.
Background: NRF2 over activity confers poor prognosis in some cancers but its prognostic role in colorectal cancer (CRC) is unknown. As a transcription factor, we hypothesise a signature of NRF2 regulated genes could act as a prognostic biomarker in CRC and reveal novel biological insights.
Methods: Using known NRF2 regulated genes, differentially expressed in CRC, we defined a signature of NRF2 pathway activity using principal component analysis and Cox proportional hazard models and tested it in four independent mRNA datasets, profiled on three different mRNA platforms.
Results: 36 genes comprised the final NRF2 signature. 1360 patients were included in the validation. High NRF2 was associated with worse disease free survival (DFS) and/or overall survival (OS) in all datasets: (GSE14333 HR=1.55, 95% C.I 1.2–2.004, p = 0.0008; GSE39582 HR=1.24, 95% C.I 1.086–1.416, p = 0.001; GSE87211 HR=1.431, 95% C.I 1.06–1.93, p = 0.056; MRC FOCUS trial HR=1.14, 95% C.I 1.04–1.26, p = 0.008). In multivariate analyses, NRF2 remained significant when adjusted for stage and adjuvant chemotherapy in stage I-III disease, and BRAF V600E mutation and sidedness in stage IV disease. NRF2 activity was particularly enriched in Consensus Molecular Subtype (CMS) 4.
Conclusion: For the first time, NRF2 is shown to be a consistent, robust prognostic biomarker across all stages of colorectal cancer with additional clinical value to current known prognostic biomarkers. High NRF2 signalling in CMS 4 further refines the molecular taxonomy of CRC, a new biological insight, suggesting avenues of further study.
1-10
O'Cathail, Séan M.
56b42a11-1955-45f0-a790-7e3512dfb941
Wu, Chieh-Hsi
ace630c6-2095-4ade-b657-241692f6b4d3
Lewis, Annabelle
028f9aa4-a580-4366-ad83-577ebf7b9fc6
Holmes, Chris
a4d53eee-2215-4c7c-a680-ec13202a629f
Hawkins, Maria A
fe46c6fb-a77c-4308-8861-48b34a65c2f3
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395
October 2020
O'Cathail, Séan M.
56b42a11-1955-45f0-a790-7e3512dfb941
Wu, Chieh-Hsi
ace630c6-2095-4ade-b657-241692f6b4d3
Lewis, Annabelle
028f9aa4-a580-4366-ad83-577ebf7b9fc6
Holmes, Chris
a4d53eee-2215-4c7c-a680-ec13202a629f
Hawkins, Maria A
fe46c6fb-a77c-4308-8861-48b34a65c2f3
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395
O'Cathail, Séan M., Wu, Chieh-Hsi, Lewis, Annabelle, Holmes, Chris, Hawkins, Maria A and Maughan, Tim
(2020)
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.
Cancer Genetics, 248-249, .
(doi:10.1016/j.cancergen.2020.08.006).
Abstract
We hypothesise that the NRF2 transcription factor would act a biomarker of poor prognosis in colorectal cancer. We derived and validated an mRNA based metagene signature of NRF2 signalling and validated it in 1360 patients from 4 different datasets as an independent biomarker of poor prognosis. This is a novel insight into the molecular signalling of colorectal cancer.
Background: NRF2 over activity confers poor prognosis in some cancers but its prognostic role in colorectal cancer (CRC) is unknown. As a transcription factor, we hypothesise a signature of NRF2 regulated genes could act as a prognostic biomarker in CRC and reveal novel biological insights.
Methods: Using known NRF2 regulated genes, differentially expressed in CRC, we defined a signature of NRF2 pathway activity using principal component analysis and Cox proportional hazard models and tested it in four independent mRNA datasets, profiled on three different mRNA platforms.
Results: 36 genes comprised the final NRF2 signature. 1360 patients were included in the validation. High NRF2 was associated with worse disease free survival (DFS) and/or overall survival (OS) in all datasets: (GSE14333 HR=1.55, 95% C.I 1.2–2.004, p = 0.0008; GSE39582 HR=1.24, 95% C.I 1.086–1.416, p = 0.001; GSE87211 HR=1.431, 95% C.I 1.06–1.93, p = 0.056; MRC FOCUS trial HR=1.14, 95% C.I 1.04–1.26, p = 0.008). In multivariate analyses, NRF2 remained significant when adjusted for stage and adjuvant chemotherapy in stage I-III disease, and BRAF V600E mutation and sidedness in stage IV disease. NRF2 activity was particularly enriched in Consensus Molecular Subtype (CMS) 4.
Conclusion: For the first time, NRF2 is shown to be a consistent, robust prognostic biomarker across all stages of colorectal cancer with additional clinical value to current known prognostic biomarkers. High NRF2 signalling in CMS 4 further refines the molecular taxonomy of CRC, a new biological insight, suggesting avenues of further study.
Text
1-s2.0-S2210776220302623-main
- Version of Record
More information
Accepted/In Press date: 17 August 2020
e-pub ahead of print date: 21 August 2020
Published date: October 2020
Identifiers
Local EPrints ID: 453347
URI: http://eprints.soton.ac.uk/id/eprint/453347
PURE UUID: 9d9fab27-10cd-4e4c-98a3-9a4e4a44b87e
Catalogue record
Date deposited: 13 Jan 2022 17:52
Last modified: 17 Mar 2024 04:00
Export record
Altmetrics
Contributors
Author:
Séan M. O'Cathail
Author:
Annabelle Lewis
Author:
Chris Holmes
Author:
Maria A Hawkins
Author:
Tim Maughan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics